Shares of Agile Therapeutics Inc. (NASDAQ:AGRX) shot up 2.9% on Wednesday . The stock traded as high as $8.15 and last traded at $7.54, with a volume of 59,012 shares changing hands. The stock had previously closed at $7.33.

Several brokerages recently weighed in on AGRX. FBR & Co reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Thursday, June 2nd. Cantor Fitzgerald reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Tuesday, May 31st. Noble Financial reiterated a “buy” rating and issued a $15.00 price objective on shares of Agile Therapeutics in a research report on Tuesday, August 9th. Finally, Zacks Investment Research downgraded shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Agile Therapeutics has an average rating of “Buy” and an average target price of $15.00.

The company has a 50 day moving average price of $7.04 and a 200-day moving average price of $6.68. The company’s market cap is $217.37 million.

Agile Therapeutics (NASDAQ:AGRX) last announced its earnings results on Monday, August 8th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.29). Analysts anticipate that Agile Therapeutics Inc. will post ($1.26) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Agile Therapeutics stock. Marshall Wace LLP increased its position in Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned about 0.58% of Agile Therapeutics worth $1,267,000 as of its most recent SEC filing.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.